EE186 Assessment of the Cost-Effectiveness of Secukinumab Versus Risankizumab for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the UK
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.436
https://www.valueinhealthjournal.com/article/S1098-3015(22)02640-7/fulltext
Title :
EE186 Assessment of the Cost-Effectiveness of Secukinumab Versus Risankizumab for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02640-7&doi=10.1016/j.jval.2022.09.436
First page :
Section Title :
Open access? :
No
Section Order :
12240